An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice
NCT ID: NCT02552940
Last Updated: 2018-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
140 participants
OBSERVATIONAL
2015-10-31
2017-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
NCT01362062
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis
NCT02087696
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
NCT02616328
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
NCT00531817
A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)
NCT02534311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rheumatoid Arthritis participants treated with Tocilizumab SC
Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Tocilizumab
Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tocilizumab
Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants in whom the treating physician has made the decision to commence TCZ SC in accordance with the label and reimbursement criteria
Exclusion Criteria
* Participants who have previously received TCZ SC
* Participants who have received treatment with any investigational agent within 4 weeks before starting treatment with TCZ SC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
nv Roche sa
UNKNOWN
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ASZ Aalst
Aalst, , Belgium
AZ Sint Lucas Brugge
Assebroek, , Belgium
AZ Sint Jan
Bruges, , Belgium
CHU St Pierre (César de Paepe)
Brussels, , Belgium
HIS (Etterbeek Ixelles)
Brussels, , Belgium
Hospital Erasme; Neurologie
Brussels, , Belgium
AZ Sint Blasius (Dendermonde)
Dendermonde, , Belgium
UZ Antwerpen
Edegem, , Belgium
Reumacentrum Genk
Genk, , Belgium
Reumaclinic
Genk, , Belgium
GHdC Site Saint-Joseph
Gilly (Charleroi), , Belgium
AZ Groeninge
Kortrijk, , Belgium
CHU Sart-Tilman
Liège, , Belgium
Private Practice
Lokeren, , Belgium
CHU UCL Mont-Godinne
Mont-godinne, , Belgium
AZ Damiaan
Ostend, , Belgium
AZ Oudenaarde
Oudenaarde, , Belgium
AZ Alma vzw (Sijsele)
Sijsele, , Belgium
AZ Sint Jozef Malle
Westmalle, , Belgium
Sint Augustinus Wilrijk
Wilrijk, , Belgium
CVBA Diagnosecentrum Voorkempen
Zoersel, , Belgium
Höpital Kirchberg; Rheumatology
Luxembourg, , Luxembourg
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML29691
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.